Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
Cure Ventures is a life sciences venture capital firm founded in 2021 and headquartered in Boston, Massachusetts. The firm specializes in the formation of new companies that focus on groundbreaking curative technologies. With a commitment to addressing life-altering diseases, Cure Ventures employs a collaborative approach, working closely with entrepreneurs to develop therapeutics that can significantly improve patient outcomes. The firm has successfully built a diverse portfolio of 12 companies, showcasing its ability to identify and support innovative solutions in the biotech and healthcare sectors.
Since its inception, Cure Ventures has raised funds that enable it to invest at various stages, including seed, Series A, and growth equity. The firm’s leadership comprises experienced professionals who bring a wealth of knowledge in life sciences and venture capital, enhancing its reputation in the market. Cure Ventures is recognized for its strategic focus on de novo company formation, which allows it to nurture startups from the ground up, ensuring that they are well-positioned for success in a competitive landscape.
Cure Ventures has a distinct investment focus centered on de novo company formation within the life sciences sector. The firm’s investment strategy is built on three core tenets: a seed funding model designed to de-risk scientific endeavors, genetic validation to increase the likelihood of success, and the active involvement of embedded Cure operators who collaborate with founders on day-to-day decision-making. This approach not only provides financial backing but also operational support, which is crucial for early-stage companies navigating the complexities of the biotech landscape.
The firm primarily invests in sectors such as biotech and healthcare, targeting innovative companies that are developing curative technologies. Cure Ventures seeks to partner with entrepreneurs who are passionate about creating solutions for life-altering diseases. By focusing on genetic validation, the firm enhances the probability of success for its portfolio companies, ensuring that they are grounded in scientific rigor. The collaborative nature of Cure Ventures’ investment strategy sets it apart, as it fosters a supportive environment where founders can thrive and bring their visions to fruition.
Cure Ventures boasts a diverse portfolio of 12 innovative companies, each focused on addressing significant challenges in the life sciences sector. Notable investments include Aevum, which is developing therapeutic molecules aimed at treating Parkinson’s disease; Alessatherapeutics, dedicated to advancing anti-androgen therapy for prostate diseases; and Cenos, which is creating a blood-brain barrier shuttle platform to enhance drug delivery to the brain. Other key portfolio companies include Clasp, innovating in precision immuno-oncology, and Recuro, which offers a virtual-first care delivery platform designed to improve patient access to healthcare services.
The firm’s portfolio reflects its commitment to supporting groundbreaking solutions that have the potential to transform patient care. By investing in a range of therapeutic areas, Cure Ventures is positioned to make a significant impact on the healthcare landscape, driving advancements that can lead to better health outcomes for patients worldwide.
To pitch Cure Ventures, founders should visit their website at curevc.com or email info@curevc.com. The firm is open to pitches that align with their focus on life sciences and curative technologies, and they encourage both warm introductions and cold applications.
Cure Ventures invests at various stages, including seed, Series A, and growth equity. This multi-stage approach allows the firm to support companies throughout their development journey, from initial formation to scaling operations.
Founders interested in pitching Cure Ventures can do so through their website at curevc.com or by emailing info@curevc.com. The firm welcomes pitches that align with their focus on life sciences and curative technologies.
Cure Ventures primarily focuses on the biotech and healthcare sectors. The firm is particularly interested in companies that are developing innovative solutions for life-altering diseases through curative technologies.
While specific check sizes are not detailed in the source material, Cure Ventures employs a seed funding model, indicating that they provide initial capital to de-risk scientific endeavors. This suggests that their investments are tailored to the needs of early-stage companies.
Cure Ventures has a geographic focus primarily on North America. This allows the firm to engage closely with the vibrant life sciences ecosystem present in the region.
Cure Ventures offers significant operational support through embedded operators who work alongside founders. This collaborative approach enhances the decision-making capabilities of portfolio companies, providing them with the resources needed to navigate challenges effectively.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.